JAMES ADAMO: Open Payments
NPI 1851311021 · ROSEVILLE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,082 in 311 payments from 26 companies in 2025. Trend: 2023 $6,780 · 2024 $5,050 · 2025 $6,082
Food & beverage: $6,075Education: $8
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 27 | $666 |
| ABBVIE INC. | 24 | $494 |
| Axsome Therapeutics, Inc. | 25 | $493 |
| Vanda Pharmaceuticals Inc. | 21 | $481 |
| Teva Pharmaceuticals USA, Inc. | 24 | $435 |
| Otsuka America Pharmaceutical, Inc. | 18 | $426 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $415 |
| Corium, LLC | 19 | $391 |
| E.R. Squibb & Sons, L.L.C. | 22 | $384 |
| Tris Pharma Inc | 18 | $260 |
Products named: INGREZZA, Auvelity, FANAPT, VRAYLAR, CAPLYTA, REXULTI, Azstarys, COBENFY.
Industry payments across MI — which companies pay providers there.
